Navigation Links
Arpida to Discuss Strategy With Shareholders
Date:5/7/2009

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd. (SIX: ARPN) will today discuss potential strategic scenarios with its shareholders during the Annual General Meeting (AGM) which starts at 10am CET in Reinach, Switzerland.

After the negative FDA opinion regarding intravenous iclaprim, Arpida has initiated a thorough analysis with the aim to design a roadmap towards approval. The company was supported by international experts in this field.

As Arpida lacks both the time and the money to complete this path, a search for funding or other strategic options took place in parallel. The search for fresh funds did not yield any results as access to credit lines or equity funding is not available.

During the last months, Arpida, supported by external advisors, has explored all other strategic scenarios, including 'reverse mergers', takeovers, asset sales as well as liquidation as a last resort.

Board and Management currently pursue business development contacts with 72 companies, both inside Switzerland and abroad. Of these, Arpida focuses on 5 that have advanced into negotiations which are currently ongoing. At today's meeting no vote is planned on this item, as no concrete proposal is available at this time. If and when a major strategic proposal is made, shareholders will obviously be duly involved.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Arpida contacts:

    Dr Jurgen Raths, President and CEO,Tel: +41-61-417-96-60;
    Harry Welten, MBA, CFO and Senior Vice President,Tel: +41-61-417-96-65;
    Paul Verbraeken, Head of Corporate Communications,Tel: +41-61-417-96-83.



'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Arpida to Restructure and Focus on Key Projects
3. Arpidas iclaprim MAA Accepted for Review by EMEA
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Arpida Announces Conference Call on 17 April
9. Arpida Announces Agenda Items for Shareholders Meeting
10. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
11. Arpida Announces Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... three months ended December 31, 2016. SQI ... diagnostics company that develops and commercializes proprietary technologies and products ... ... commercial milestones achieved in fiscal 2016," said Andrew Morris ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... and development (R&D), today announced the establishment of Genedata Limited as a new ... Teburi, a recognized expert in life science informatics. Creating the UK subsidiary reinforces ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Treximo will pair its $200M operational capacity with its strategic internal leadership ... in areas affecting quality and operational management. With office locations in ...
(Date:2/21/2017)... BOTHELL, Wash. and VANCOUVER, British Columbia ... OGXI ) today announced that apatorsen results from ... American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, ... Orlando . Clinical data from trials in bladder ... outcomes when administered in combination with standard-of-care treatments. ...
Breaking Biology Technology:
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):